as declared in bloomberg
Novartis Pullback Fuels Doubts on Novel CAR-T Cancer Therapy
Novartis Pullback Fuels Doubts on Novel CAR-T Cancer Therapy
Novartis AG's decision to fold a unit that was working on a novel cancer therapy casts doubt on other companies that are betting on what's seen as one of the most exciting approaches to fighting the disease.In a surprise move Wednesday, the Swiss drugmaking giant, a champion of the experimental therapy known as CAR-T, said research related to it would no longer be housed in a separate division, leading to 120 job cuts mostly in the U.S."It strikes me as they're viewing this as an interesting state-of-the-art science project that may only have limited application in the real world from a commercial perspective," said David Pinniger, who manages the Polar Capital Biotechnology Fund and doesn't hold shares of Juno or Kite."This smacks of someone big, knowledgeable and sophisticated just pulling back."Novartis's decision to dissolve its gene and cell therapies unit added to recent setbacks for the promising therapy, in which a patient's immune system cells are taken out, genetically engineered to recognize tumors, and reinfused.
in the same way newsmax
Expectations May Influence Side Effects of Breast Cancer Hormone Therapy
Expectations May Influence Side Effects of Breast Cancer Hormone Therapy
Side effects from taking tamoxifen for breast cancer may be worse if a patient expects they will be bad before therapy even begins, according to a recent study from Germany.Over a two-year period, women who expected more serious side effects before treatment started experienced almost twice as many symptoms as women who thought the therapy wouldn't be too terrible.Since side effects can lead some women to stop taking their medication, patient expectations are an important factor for doctors to consider and possibly modify to improve treatment success, Yvonne Nestoriuc of the University Medical Center Hamburg-Eppendorf and her coauthors write in Annals of Oncology.
in like manner medgadget
Small Molecule Targeted Cancer Therapy Market 2016: Global Industry Review, Research, Statistics, and Growth to 2022
Small Molecule Targeted Cancer Therapy Market 2016: Global Industry Review, Research, Statistics, and Growth to 2022
Small Molecule Targeted Cancer Therapy is the medication that blocks the cancerous cells growth by destroying the targeted molecules that result in the growth of tumor and carcinogenesis.Conventional chemotherapies and cytotoxin medications destroy the division of cancerous cells by inhibiting the process of cell division.Targeted Cancer therapy is considered to be more effective than the conventional methods and prevent normal cells from harmful radiations.
No comments:
Post a Comment